Hsa-let-7b Suppresses Cell Proliferation by Targeting UHRF1 in Melanoma

References

• Kim JK, Estève PO, Jacobsen SE, Pradhan S. UHRF1 binds G9a and participates in p21 transcriptional regulation in mammalian cells. Nucleic Acids Res. 2009;37(2):493–505. doi:10.1093/nar/gkn961.
   PubMed Web of Science ®Google Scholar
• Hopfner R, Mousli M, Jeltsch JM, Voulgaris A, Lutz Y, Marin C, et al. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression. Cancer Res. 2000;60(1):121–128.
   PubMed Web of Science ®Google Scholar
• Pi JT, Lin Y, Quan Q, Chen LL, Jiang LZ, Chi W, et al. Overexpression of UHRF1 is significantly associated with poor prognosis in laryngeal squamous cell carcinoma. Med Oncol. 2013;30(4):613. doi:10.1007/s12032-013-0613-9.
   PubMed Web of Science ®Google Scholar
• Zhou L, Shang Y, Jin Z, Zhang W, Lv C, Zhao X, et al. UHRF1 promotes proliferation of gastric cancer via mediating tumor suppressor gene hypermethylation. Cancer Biol Ther. 2015;16(8):1241–1251. doi:10.1080/15384047.2015.1056411.
   PubMed Web of Science ®Google Scholar
• Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509–524. doi:10.1038/nrm3838.
   PubMed Web of Science ®Google Scholar
• He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–531. doi:10.1038/nrg1379.
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol. 2012;81(2):103–122. doi:10.1016/j.critrevonc.2011.03.010.
   PubMed Web of Science ®Google Scholar
• Kumar MS, Armenteros-Monterroso E, East P, Chakravorty P, Matthews N, Winslow MM, et al. HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature. 2014;505(7482):212–217. doi:10.1038/nature12785.
   PubMed Web of Science ®Google Scholar
• Winter J, Diederichs S. MicroRNA biogenesis and cancer. Methods Mol Biol. 2011;676:3–22.
   PubMedGoogle Scholar
• Dai J, Hu Z, Jiang Y, Shen H, Dong J, Ma H, et al. Breast cancer risk assessment with five independent genetic variants and two risk factors in Chinese women. Breast Cancer Res. 2012;14(1):R17. doi:10.1186/bcr3101.
   PubMed Web of Science ®Google Scholar
• Rehmsmeier M. Fast and effective prediction of microRNA/target duplexes. RNA. 2004;10(10):1507–1517. doi:10.1261/rna.5248604.
   PubMed Web of Science ®Google Scholar
• Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol. 2013;15(2):201–213. doi:10.1038/ncb2672.
   PubMed Web of Science ®Google Scholar
• Lagos-Quintana M. Identification of novel genes coding for small expressed RNAs. Science. 2001;294(5543):853–858. doi:10.1126/science.1064921.
   PubMed Web of Science ®Google Scholar
• Pencheva N, Tran H, Buss C, Huh D, Drobnjak M, Busam K, et al. Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell. 2012;151(5):1068–1082. doi:10.1016/j.cell.2012.10.028.
   PubMed Web of Science ®Google Scholar
• Bell RE, Khaled M, Netanely D, Schubert S, Golan T, Buxbaum A, et al. Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1. J Invest Dermatol. 2014;134(2):441–451. doi:10.1038/jid.2013.340.
   PubMed Web of Science ®Google Scholar
• Poenitzsch SA, Setaluri V, Spiegelman VS. MicroRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma. Arch Biochem Biophys. 2014;563:118–124. doi:10.1016/j.abb.2014.07.012.
   PubMed Web of Science ®Google Scholar
• Yang Y, Sun X, Liu J, Kang L, Chen S, Ma B, et al. miRNA signature identification of retinoblastoma and the correlations between differentially expressed miRNAs during retinoblastoma progression. Mol Vis. 2016;21(10):1307–1317.
   Google Scholar
• Bronner C, Krifa M, Mousli M. Increasing role of UHRF1 in the reading and inheritance of the epigenetic code as well as in tumorogenesis. Biochem Pharmacol. 2013;86(12):1643–1649. doi:10.1016/j.bcp.2013.10.002.
   PubMed Web of Science ®Google Scholar
• Ashraf W, Ibrahim A, Alhosin M, Zaayter L, Ouararhni K, Papin C, et al. The epigenetic integrator UHRF1: on the road to become a universal biomarker for cancer. Oncotarget. 2017;8(31):51946–51962. doi:10.18632/oncotarget.17393.
   PubMedGoogle Scholar
• Cui L, Chen J, Zhang Q, Wang X, Qu J, Zhang J, et al. Up-regulation of UHRF1 by oncogenic Ras promoted the growth, migration, and metastasis of pancreatic cancer cells. Mol Cell Biochem. 2015;400(1-2):223–232. doi:10.1007/s11010-014-2279-9.
   PubMed Web of Science ®Google Scholar
• Mousli M, Hopfner R, Abbady AQ, Monté D, Jeanblanc M, Oudet P, et al. ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells. Br J Cancer. 2003;89(1):120–127. doi:10.1038/sj.bjc.6601068.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang X, Su Z, Fei H, Liu X, Pan Q. The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth. Oncol Rep. 2015;34(4):1708–1716. doi:10.3892/or.2015.4146.
   PubMed Web of Science ®Google Scholar
• Zhou L, Zhao X, Han Y, Lu Y, Shang Y, Liu C, et al. Regulation of UHRF1 by miR-146a/b modulates gastric cancer invasion and metastasis. FASEB J. 2013;27(12):4929–4939. doi:10.1096/fj.13-233387.
   PubMed Web of Science ®Google Scholar
• Wang X, Wu Q, Xu B, Wang P, Fan W, Cai Y, et al. MiR-124 exerts tumor suppressive functions on the cell proliferation, motility and angiogenesis of bladder cancer by fine-tuning UHRF1. FEBS J. 2015;282(22):4376–4388. doi:10.1111/febs.13502.
   PubMed Web of Science ®Google Scholar
• Matsushita R, Yoshino H, Enokida H, Goto Y, Miyamoto K, Yonemori M, et al. Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): inhibition of bladder cancer cell aggressiveness. Oncotarget. 2016;7(19):28460–28487. doi:10.18632/oncotarget.8668.
   PubMedGoogle Scholar
• Wotschofsky Z, Gummlich L, Liep J, Stephan C, Kilic E, Jung K, et al. Integrated microRNA and mRNA signature associated with the transition from the locally confined to the metastasized clear cell renal cell carcinoma exemplified by miR-146-5p. PLoS One. 2016;11(2):e0148746. doi:10.1371/journal.pone.0148746.
   PubMed Web of Science ®Google Scholar
• Deng W, Yan M, Yu T, Ge H, Lin H, Li J, et al. Quantitative proteomic analysis of the metastasis-inhibitory mechanism of miR-193a-3p in non-small cell lung cancer. Cell Physiol Biochem. 2015;35(5):1677–1688. doi:10.1159/000373981.
   PubMedGoogle Scholar
• Reid G, Kao SC, Pavlakis N, Brahmbhatt H, MacDiarmid J, Clarke S, et al. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics. 2016;8(8):1079–1085. doi:10.2217/epi-2016-0035.
   PubMed Web of Science ®Google Scholar
• Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017;35(2):180–188. doi:10.1007/s10637-016-0407-y.
   PubMed Web of Science ®Google Scholar
• Choudhry H, Zamzami MA, Omran Z, Wu W, Mousli M, Bronner C, et al. Targeting microRNA/UHRF1 pathways as a novel strategy for cancer therapy. Oncol Lett. 2018;15(1):3–10. doi:10.3892/ol.2017.7290.
   PubMed Web of Science ®Google Scholar